NEW YORK (GenomeWeb) – ERS Genomics today announced that it has non-exclusively licensed patents related to CRISPR-Cas9 genome-editing technology to Regeneron Pharmaceuticals for use in drug discovery and development.
Specific terms of the deal were not disclosed.
ERS was founded to provide broad access to the intellectual property, which is based on the research of Emmanuelle Charpentier from the Hannover Medical School in Germany and Umea University in Sweden.
"Genome editing has many applications in drug discovery and development and making the CRISPR-Cas9 patents widely available to biotechnology and pharmaceutical companies is an important part of ERS Genomics' strategy," ERS CEO and Founder Shaun Foy said in a statement.
Last year, ERS signed an agreement providing non-exclusive access to the IP to Horizon Discovery for research applications.